Usefulness of Speckle Tracking Echocardiography and Biomarkers for Detecting Acute Cellular Rejection After Heart Transplantation

Cruz, Cecília Beatriz Bittencourt Viana; Hajjar, Ludhmila Abrahão; Bacal, Fernando; Lofrano-Alves, Marco S.; Lima, Márcio Silva Miguel; Abduch, Maria Cristina Donadio; Viera, Marcelo L.C.; Chiang, Hsu Po; Salviano, Juliana B. C.; costa, isabela bispo; Fukushima, Júlia Tizue; Sbano, João; Mathias, Wilson; Tsutsui, Jeane Mike

doi:10.21203/rs.3.rs-96047/v1

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limitations of this study are noteworthy. It is worth noting that the gold standard for diagnosing AIC is still endomyocardial biopsy (EMB) (33). However, EMB is associated with complications and is limited in its clinical application (34,35).…”

Section: Discussionmentioning

confidence: 99%

Cardioprotective effect of saffron total glycoside tablets in patients with breast cancer receiving anthracycline-based chemotherapy: study protocol for a multicentre, randomised, parallel, double-blind, placebo-controlled clinical trial

Su¹,

Li²,

Zhang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Breast cancer is the most common cancer worldwide. Anthracyclines, alone or in combination with other chemotherapeutic agents, are the most effective chemotherapy agents against breast cancer.However, the dose-dependent cardiotoxicity of anthracyclines is a serious drawback in clinical treatment.Considerable efforts have been made to establish suggestions to avoid anthracycline-induced cardiotoxicity.Crocin extracted from saffron has potential cardioprotective effects against anthracycline-induced cardiotoxicity.The aim of this study was to estimate the cardioprotective effects and safety of saffron total glycoside tablets relative to placebo in patients with breast cancer undergoing anthracycline-based chemotherapy.Methods: This is a multicentre, randomised, double-blind, placebo-controlled clinical trial. A sample of 200 participants (100 per group) with breast cancer will be randomly assigned to receive either saffron total glycoside tablet or placebo (four tablets each time, three times each day) for 6 months. Each participant will be interviewed three times: baseline (visit 1), after 3 months (visit 2), and after 6 months (visit 3). The primary outcome is to confirm if administration of saffron total glycoside tablets reduces the rate of cardiotoxicity relative to that with placebo. Secondary outcomes include new arrhythmic events, and cardiac troponin I and N-terminal pro-B-type natriuretic peptide levels. The quantity, quality, and severity of the adverse events will be carefully documented.Discussion: We look forward to obtaining high-quality evidence that can be used to formulate clinical practice guidelines. Thus, the findings of this study are expected to help fill the current gap in cardiotoxicity prevention drugs. Trial registration: This trial was published in the Chinese Clinical Trial Registry (No. ChiCTR2000041134, registered on 19th December 2020).

show abstract

Section: Discussionmentioning

confidence: 99%